ACM
ACAD icon

Allred Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Allred Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,000
Closed -$51.6K – 188
2021
Q1 		$51.6K Buy
+2,000
New +$88K 0.02% 377

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Allred Capital Management's ACAD Position: Q2 2021 in Review

Allred Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 2,000 shares — an estimated $51.6K sold.

Allred Capital Management first reported a position in ACAD in Q1 2021 and held it in 1 quarter. The position peaked at $51.6K in Q1 2021. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • Allred Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Allred Capital Management sold 2,000 Acadia Pharmaceuticals shares in Q2 2021, an estimated $51.6K.
  • Allred Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Allred Capital Management's Acadia Pharmaceuticals position peaked at $51.6K in Q1 2021.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Allred Capital Management's 13F filing for Q2 2021, filed 5 Aug 2021.